Trade vTv Therapeutics Inc. - VTVT CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.030779% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | -0.013666% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 20% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Key Stats
| Prev. Close* | 0.94 |
| Open* | 0.96 |
| 1-Year Change* | 37.14% |
| Day's Range* | 0.93 - 0.96 |
| 52 wk Range | 0.38-1.40 |
| Average Volume (10 days) | 82.89K |
| Average Volume (3 months) | 1.42M |
| Market Cap | 102.09M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 104.58M |
| Revenue | 2.02M |
| EPS | -0.31 |
| Dividend (Yield %) | N/A |
| Beta | -1.09 |
| Next Earnings Date | Mar 27, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 27, 2023 | 0.94 | -0.02 | -2.08% | 0.96 | 0.96 | 0.93 |
| Jan 26, 2023 | 0.94 | 0.00 | 0.00% | 0.94 | 0.96 | 0.88 |
| Jan 25, 2023 | 0.95 | -0.01 | -1.04% | 0.96 | 0.96 | 0.93 |
| Jan 24, 2023 | 0.96 | 0.01 | 1.05% | 0.95 | 0.97 | 0.94 |
| Jan 23, 2023 | 0.98 | -0.01 | -1.01% | 0.99 | 1.01 | 0.98 |
| Jan 20, 2023 | 0.98 | 0.02 | 2.08% | 0.96 | 1.01 | 0.95 |
| Jan 19, 2023 | 0.95 | 0.05 | 5.56% | 0.90 | 0.96 | 0.90 |
| Jan 18, 2023 | 0.89 | 0.05 | 5.95% | 0.84 | 0.90 | 0.84 |
| Jan 17, 2023 | 0.85 | 0.03 | 3.66% | 0.82 | 0.87 | 0.80 |
| Jan 13, 2023 | 0.79 | 0.02 | 2.60% | 0.77 | 0.82 | 0.77 |
| Jan 12, 2023 | 0.78 | 0.02 | 2.63% | 0.76 | 0.79 | 0.75 |
| Jan 11, 2023 | 0.78 | 0.00 | 0.00% | 0.78 | 0.80 | 0.77 |
| Jan 10, 2023 | 0.77 | 0.00 | 0.00% | 0.77 | 0.78 | 0.75 |
| Jan 9, 2023 | 0.75 | -0.03 | -3.85% | 0.78 | 0.80 | 0.74 |
| Jan 6, 2023 | 0.75 | 0.01 | 1.35% | 0.74 | 0.75 | 0.73 |
| Jan 5, 2023 | 0.72 | -0.03 | -4.00% | 0.75 | 0.75 | 0.71 |
| Jan 4, 2023 | 0.74 | 0.07 | 10.45% | 0.67 | 0.76 | 0.66 |
| Jan 3, 2023 | 0.67 | 0.04 | 6.35% | 0.63 | 0.70 | 0.63 |
| Dec 30, 2022 | 0.64 | 0.00 | 0.00% | 0.64 | 0.66 | 0.62 |
| Dec 29, 2022 | 0.64 | 0.01 | 1.59% | 0.63 | 0.65 | 0.63 |
vTv Therapeutics Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| No events scheduled | ||
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total revenue | 0.634 | 0.291 | 12.434 | 2.764 | 6.414 | 4.005 |
| Revenue | 0.634 | 0.291 | 12.434 | 2.764 | 6.414 | 4.005 |
| Total Operating Expense | 55.654 | 50.973 | 32.258 | 23.656 | 18.266 | 25.667 |
| Selling/General/Admin. Expenses, Total | 9.906 | 11.333 | 9.223 | 8.537 | 7.251 | 11.443 |
| Research & Development | 45.748 | 39.64 | 23.035 | 15.119 | 11.015 | 12.624 |
| Operating Income | -55.02 | -50.682 | -19.824 | -20.892 | -11.852 | -21.662 |
| Interest Income (Expense), Net Non-Operating | -0.311 | -2.975 | -3.229 | -1.774 | -0.68 | -0.011 |
| Other, Net | -0.022 | -0.19 | -0.592 | 0.828 | -0.27 | 4.057 |
| Net Income Before Taxes | -55.353 | -53.847 | -23.645 | -21.838 | -12.802 | -17.616 |
| Net Income After Taxes | -55.353 | -48.8 | -23.845 | -21.938 | -12.802 | -17.731 |
| Minority Interest | 39.001 | 38.503 | 15.934 | 8.894 | 4.303 | 4.744 |
| Net Income Before Extra. Items | -16.352 | -10.297 | -7.911 | -13.044 | -8.499 | -12.987 |
| Net Income | -16.352 | -16.144 | -7.911 | -13.044 | -8.499 | -12.987 |
| Income Available to Common Excl. Extra. Items | -16.352 | -10.297 | -8.65 | -17.913 | -8.499 | -12.987 |
| Income Available to Common Incl. Extra. Items | -16.352 | -16.144 | -8.65 | -17.913 | -8.499 | -12.987 |
| Diluted Net Income | -16.352 | -16.144 | -8.65 | -17.913 | -8.499 | -12.987 |
| Diluted Weighted Average Shares | 9.54553 | 9.69325 | 12.4492 | 30.292 | 47.1379 | 60.7326 |
| Diluted EPS Excluding Extraordinary Items | -1.71305 | -1.06229 | -0.69482 | -0.59134 | -0.1803 | -0.21384 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||||
| Diluted Normalized EPS | -1.71305 | -1.06229 | -0.69482 | -0.59134 | -0.1803 | -0.19671 |
| Total Extraordinary Items | -5.847 | |||||
| Total Adjustments to Net Income | -0.739 | -4.869 | 0 | |||
| Unusual Expense (Income) | 1.6 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0.987 | 0.009 | 3 | 0.009 | 2 |
| Revenue | 0.987 | 0.009 | 3 | 0.009 | 2 |
| Total Operating Expense | 5.267 | 4.679 | 4.603 | 11.118 | 8.481 |
| Selling/General/Admin. Expenses, Total | 2.164 | 2.242 | 2.221 | 5.716 | 5.348 |
| Research & Development | 3.103 | 2.437 | 2.382 | 5.402 | 3.133 |
| Operating Income | -4.28 | -4.67 | -1.603 | -11.109 | -6.481 |
| Interest Income (Expense), Net Non-Operating | 0.001 | 0 | -0.006 | -0.006 | -0.001 |
| Other, Net | -1.648 | 3.829 | 0.244 | 1.632 | -2.742 |
| Net Income Before Taxes | -5.927 | -0.841 | -1.365 | -9.483 | -9.224 |
| Net Income After Taxes | -5.942 | -0.841 | -1.465 | -9.483 | -9.424 |
| Minority Interest | 1.701 | 0.233 | 0.378 | 2.432 | 2.417 |
| Net Income Before Extra. Items | -4.241 | -0.608 | -1.087 | -7.051 | -7.007 |
| Net Income | -4.241 | -0.608 | -1.087 | -7.051 | -7.007 |
| Income Available to Common Excl. Extra. Items | -4.241 | -0.608 | -1.087 | -7.051 | -7.007 |
| Income Available to Common Incl. Extra. Items | -4.241 | -0.608 | -1.087 | -7.051 | -7.007 |
| Diluted Net Income | -4.241 | -0.608 | -1.087 | -7.051 | -7.007 |
| Diluted Weighted Average Shares | 56.4725 | 58.6151 | 61.0733 | 66.719 | 66.9428 |
| Diluted EPS Excluding Extraordinary Items | -0.0751 | -0.01037 | -0.0178 | -0.10568 | -0.10467 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.0751 | -0.01037 | -0.0178 | -0.10568 | -0.10467 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 52.117 | 20.362 | 3.473 | 2.838 | 7.215 | 15.621 |
| Cash and Short Term Investments | 51.505 | 11.758 | 1.683 | 1.777 | 5.747 | 13.415 |
| Cash & Equivalents | 51.505 | 11.758 | 1.683 | 1.777 | 5.747 | 13.415 |
| Total Receivables, Net | 0 | 8 | 0 | 0.005 | 0.158 | 0.057 |
| Accounts Receivable - Trade, Net | 0 | 8 | 0 | 0.005 | 0.158 | 0.057 |
| Prepaid Expenses | 0.612 | 0.442 | 0.666 | 0.806 | 0.939 | 1.914 |
| Total Assets | 54.495 | 27.917 | 8.559 | 9.266 | 14.789 | 25.474 |
| Property/Plant/Equipment, Total - Net | 0.444 | 0.283 | 0.07 | 1.004 | 0.849 | 0.68 |
| Property/Plant/Equipment, Total - Gross | 10.898 | 9.399 | 8.501 | 1.152 | 1.065 | 0.985 |
| Accumulated Depreciation, Total | -10.454 | -9.116 | -8.431 | -0.148 | -0.216 | -0.305 |
| Other Long Term Assets, Total | 1.934 | 4.792 | 2.536 | 2.944 | 0 | |
| Total Current Liabilities | 11.434 | 26.929 | 18.837 | 13.381 | 6.39 | 8.498 |
| Accounts Payable | 3.06 | 2.269 | 2.899 | 2.232 | 1.925 | 1.876 |
| Payable/Accrued | 0 | |||||
| Accrued Expenses | 8.353 | 11.632 | 4.803 | 4.946 | 4.35 | 6.331 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.021 | 8.757 | 1.752 | 0.031 | 0.031 | 0.035 |
| Total Liabilities | 145.44 | 178.964 | 91.412 | 58.289 | 94.891 | 35.214 |
| Total Long Term Debt | 11.058 | 15.316 | 6.33 | 0 | 0 | 0 |
| Long Term Debt | 11.058 | 15.316 | 6.33 | 0 | ||
| Minority Interest | 122.515 | 131.44 | 62.482 | 40.183 | 83.895 | 24.962 |
| Other Liabilities, Total | 0.433 | 5.279 | 3.763 | 4.725 | 4.606 | 1.754 |
| Total Equity | -90.945 | -151.047 | -82.853 | -49.023 | -80.102 | -9.74 |
| Common Stock | 0.329 | 0.329 | 0.435 | 0.641 | 0.773 | 0.901 |
| Additional Paid-In Capital | 124.212 | 127.682 | 150.595 | 183.858 | 209.161 | 238.193 |
| Retained Earnings (Accumulated Deficit) | -215.486 | -279.058 | -233.883 | -233.522 | -290.036 | -248.834 |
| Total Liabilities & Shareholders’ Equity | 54.495 | 27.917 | 8.559 | 9.266 | 14.789 | 25.474 |
| Total Common Shares Outstanding | 32.8125 | 32.8125 | 43.4413 | 64.0127 | 77.1449 | 90.0366 |
| Other Current Assets, Total | 0.162 | 1.124 | 0.25 | 0.371 | 0.235 | |
| Long Term Investments | 2.48 | 2.48 | 2.48 | 6.725 | 9.173 | |
| Current Port. of LT Debt/Capital Leases | 4.271 | 9.383 | 6.172 | 0.084 | 0.256 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 9.221 | 11.272 | 22.171 | 15.621 | 13.612 |
| Cash and Short Term Investments | 8.449 | 10.835 | 19.566 | 13.415 | 12.138 |
| Cash & Equivalents | 8.449 | 10.835 | 19.566 | 13.415 | 12.138 |
| Total Receivables, Net | 0.002 | 0 | 0.928 | 0.057 | 0.057 |
| Accounts Receivable - Trade, Net | 0.002 | 0 | 0.928 | 0.057 | 0.057 |
| Prepaid Expenses | 0.71 | 0.313 | 1.574 | 2.049 | 1.387 |
| Other Current Assets, Total | 0.06 | 0.124 | 0.103 | 0.1 | 0.03 |
| Total Assets | 16.754 | 21.66 | 31.434 | 25.474 | 20.185 |
| Property/Plant/Equipment, Total - Net | 0.808 | 0.766 | 0.724 | 0.68 | 0.634 |
| Long Term Investments | 6.725 | 9.622 | 8.539 | 9.173 | 5.939 |
| Total Current Liabilities | 5.162 | 5.059 | 5.51 | 8.498 | 12.7 |
| Payable/Accrued | 4.965 | 4.855 | 4.663 | 8.023 | 12.474 |
| Accrued Expenses | 0.162 | 0.169 | 0.176 | 0.184 | 0.191 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0 | 0 | 0.636 | 0.256 | 0 |
| Other Current Liabilities, Total | 0.035 | 0.035 | 0.035 | 0.035 | 0.035 |
| Total Liabilities | 73.029 | 69.483 | 52.979 | 35.214 | 28.278 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 62.647 | 60.19 | 44.61 | 24.962 | 14.367 |
| Other Liabilities, Total | 5.22 | 4.234 | 2.859 | 1.754 | 1.211 |
| Total Equity | -56.275 | -47.823 | -21.545 | -9.74 | -8.093 |
| Common Stock | 0.808 | 0.834 | 0.897 | 0.901 | 0.901 |
| Additional Paid-In Capital | 217.647 | 224.457 | 236.557 | 238.193 | 238.669 |
| Retained Earnings (Accumulated Deficit) | -274.73 | -273.114 | -258.999 | -248.834 | -247.663 |
| Total Liabilities & Shareholders’ Equity | 16.754 | 21.66 | 31.434 | 25.474 | 20.185 |
| Total Common Shares Outstanding | 80.6658 | 83.2878 | 89.565 | 90.0366 | 90.0366 |
- Annual
- Quarterly
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|
| Net income/Starting Line | -55.353 | -54.647 | -23.845 | -21.938 | -12.802 | -17.731 |
| Cash From Operating Activities | -48.209 | -44.56 | -26.856 | -23.018 | -18 | -19.308 |
| Cash From Operating Activities | 0.265 | 0.197 | 0.218 | 0.039 | 0.094 | 0.089 |
| Non-Cash Items | 2.793 | 4.853 | 4.316 | 0.935 | -2.586 | -1.701 |
| Cash Interest Paid | 0.242 | 2.064 | 2.276 | 1.295 | 0.623 | 0.011 |
| Changes in Working Capital | 4.086 | 5.037 | -7.545 | -2.054 | -2.706 | 0.035 |
| Cash From Investing Activities | -0.083 | -0.025 | 0.007 | 0.242 | 0 | 0 |
| Capital Expenditures | -0.087 | -0.057 | -0.005 | -0.07 | 0 | 0 |
| Other Investing Cash Flow Items, Total | 0.004 | 0.032 | 0.012 | 0.312 | 0 | 0 |
| Cash From Financing Activities | 11.794 | 7.5 | 16.612 | 22.87 | 19.47 | 26.976 |
| Financing Cash Flow Items | -0.673 | 0 | 0 | |||
| Issuance (Retirement) of Stock, Net | 0 | 0 | 21.5 | 32.943 | 24.426 | 26.804 |
| Issuance (Retirement) of Debt, Net | 12.467 | 7.5 | -4.888 | -10.073 | -4.956 | 0.172 |
| Net Change in Cash | -36.498 | -37.085 | -10.237 | 0.094 | 1.47 | 7.668 |
| Cash Taxes Paid | 1 | 0.1 | 0 | 0.115 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -5.942 | -6.783 | -8.248 | -17.731 | -9.424 |
| Cash From Operating Activities | -5.299 | -9.297 | -12.891 | -19.308 | -1.021 |
| Cash From Operating Activities | 0.023 | 0.045 | 0.067 | 0.089 | 0.023 |
| Non-Cash Items | 2.084 | -1.292 | -1.063 | -1.701 | 3.218 |
| Changes in Working Capital | -1.464 | -1.267 | -3.647 | 0.035 | 5.162 |
| Cash From Financing Activities | 8.001 | 14.385 | 26.71 | 26.976 | -0.256 |
| Issuance (Retirement) of Stock, Net | 8.085 | 14.469 | 26.158 | 26.804 | 0 |
| Issuance (Retirement) of Debt, Net | -0.084 | -0.084 | 0.552 | 0.172 | -0.256 |
| Net Change in Cash | 2.702 | 5.088 | 13.819 | 7.668 | -1.277 |
| Cash From Investing Activities | 0 | ||||
| Capital Expenditures | 0 | ||||
| Other Investing Cash Flow Items, Total | 0 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| MacAndrews & Forbes Holdings, Inc. | Holding Company | 44.9246 | 36606212 | 87000 | 2022-05-31 | LOW |
| G42 Investments AI Holdings RSC, Ltd. | Corporation | 12.7465 | 10386274 | 10386274 | 2022-05-31 | LOW |
| Medpace Investors, L.L.C. | Corporation | 6.6241 | 5397529 | 5397529 | 2022-08-16 | LOW |
| Samsara BioCapital, LLC | Venture Capital | 2.0072 | 1635509 | 0 | 2022-09-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.1523 | 938970 | 0 | 2022-09-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3559 | 290000 | -76618 | 2022-09-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1654 | 134745 | -71400 | 2022-09-30 | LOW |
| Millennium Management LLC | Hedge Fund | 0.0949 | 77339 | -61344 | 2022-09-30 | HIGH |
| Fry (John Anthony) | Individual Investor | 0.0749 | 61000 | 61000 | 2022-11-29 | LOW |
| Nelson (Rich S) | Individual Investor | 0.0736 | 60000 | 0 | 2022-04-04 | |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.0661 | 53845 | -287 | 2022-09-30 | LOW |
| Virtu Americas LLC | Research Firm | 0.0539 | 43954 | 5395 | 2022-09-30 | HIGH |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.0498 | 40577 | 0 | 2022-09-30 | LOW |
| PGIM Quantitative Solutions LLC | Investment Advisor | 0.0491 | 40000 | 0 | 2022-09-30 | LOW |
| Morgan Stanley Smith Barney LLC | Investment Advisor | 0.041 | 33442 | 0 | 2022-09-30 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.0405 | 33012 | -4256 | 2022-09-30 | HIGH |
| Two Sigma Investments, LP | Hedge Fund | 0.0397 | 32385 | 14590 | 2022-09-30 | HIGH |
| Simon Quick Advisors, LLC | Investment Advisor | 0.0368 | 30000 | 0 | 2022-09-30 | MED |
| Bridgeway Capital Management, LLC | Investment Advisor | 0.0332 | 27018 | 27018 | 2022-09-30 | LOW |
| Kozlov (Hersh) | Individual Investor | 0.0307 | 25000 | 0 | 2022-04-04 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group +485000+
Traders
65000+
Active clients monthly
$48000000+
Monthly investing volume
$28000000+
Try now Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
Leverage
20:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
vTv Therapeutics Inc. Company profile
About vTv Therapeutics Inc
vTv Therapeutics Inc. is a clinical-stage pharmaceutical company that is engaged in the discovery and development of orally administered small molecule drug candidates. It is developing a program for the treatment of type I diabetes TTP399 and for psoriasis HPP737. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. The Company is also conducting a multiple ascending dose Phase I study of HPP737, an orally administered phosphodiesterase type IV inhibitor, to assess the pharmacokinetics, pharmacodynamics, safety and tolerability of HPP737 in healthy volunteers as part of its psoriasis program. Its TTP273 is an oral, small molecule, glucagon-like peptide I (GLP-1) receptor agonist being evaluated for the treatment of type II diabetes mellitus.
Financial summary
BRIEF: For the nine months ended 30 September 2021, vTv Therapeutics Inc revenues increased from $15K to $4M. Net loss decreased 38% to $5.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Other (expense) income increase from $0K to $1.8M (income), Research and Development - Balancing decrease of 10% to $7.4M (expense).
| Industry: | Bio Therapeutic Drugs |
3980 Premier Dr
Suite 310
HIGH POINT
NORTH CAROLINA 27265
US
Income Statement
- Annual
- Quarterly
News
FX Weekly Outlook: USD, GBP/USD, EUR/USD Analysis
USD, GBP/USD, EUR/USD forecasts for the week ahead.
16:33, 27 January 2023
WTI, Gold, Silver – commodities weekly forecast for the week ahead
Strength to strength in the commodity space, however, topside exhaustion begins to creep in
13:53, 27 January 2023
S&P 500, Nasdaq, DAX 40, Hang Seng technical update
Can the S&P 500 hold above its 2022 descending trend line?
12:44, 26 January 2023
Amazon Q4 earnings: online retailer to feel the pinch of higher costs and slowing consumer spending
AMZN Q4 earnings preview and technical analysis
09:59, 25 January 2023
Canadian Dollar Forecast: Bank of Canada Heading Towards a Final Rate Hike
Bank of Canada expected to hike 25bps at its upcoming meeting. Focus on whether the BoC announces a pause going forward.
15:49, 24 January 2023People also watch
Still looking for a broker you can trust?
Join the 480.000+ traders worldwide that chose to trade with Capital.com